Positive efficacy and durability data reinforce anzu-cel's potential in melanoma; investors should watch for SUPRAME Phase 3 enrollment progress and any competitive developments. The 1H 2027 BLA submission timeline provides a medium-term catalyst.
Price Chart
Executive Summary
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, showing 56% confirmed ORR, 14.6-month median DOR, 6.1-month median PFS, and 16.2-month median OS with manageable safety. The Phase 3 SUPRAME trial remains on track with BLA submission expected in 1H 2027.
Key Facts
- 56% confirmed objective response rate (cORR) in heavily pretreated metastatic melanoma (N=33)
- Median duration of response (mDOR) of 14.6 months; median PFS 6.1 months; median OS 16.2 months
- Phase 3 SUPRAME trial advancing; BLA submission targeted for 1H 2027
- Predictable and manageable safety profile with mostly Grade 1-2 CRS and infrequent ICANS
- Anzu-cel demonstrated systemic anti-tumor activity across multiple metastatic sites including liver, lung, and brain
Financial Impact
Positive clinical data supports the potential of anzu-cel as a first-in-class PRAME-directed cell therapy, though no financial figures provided.
Risk Factors
- Data is from Phase 1b; Phase 3 may not replicate results
- Competitive landscape includes approved checkpoint inhibitors and other cell therapies
- Regulatory approval and commercial launch are uncertain and costly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.59 (−19.68%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.59 (+18.91%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.59 (−16.50%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.59 (−24.40%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.59 (−31.87%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.59 (+33.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access